In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate Cancer Models

• Published in: The Prostate Vol. 66; no. 7; pp. 708 - 717
• Main Authors: Fricke, Stanley T., Rodriguez, Olga, VanMeter, John, Dettin, Luis E., Casimiro, Mathew, Chien, Christopher D., Newell, Tionanatasha, Johnson, Kevin, Ileva, Lilia, Ojeifo, John, Johnson, Michael D., Albanese, Chris
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.05.2006
• Subjects: Animals; Disease Models, Animal; ErbB-2; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Mice; mouse models; MRI; prostate cancer; Prostatic Neoplasms - pathology; Prostatic Neoplasms - veterinary; Pten; spectroscopy
• ISSN: 0270-4137; 1097-0045
• DOI: 10.1002/pros.20392

BACKGROUND Mouse prostate cancer modeling presents unique obstacles to the study of spontaneous tumor initiation and progression due to the anatomical location of the tissue. RESULTS High resolution (130 µmx × 130 µmy × 300 µmz), three‐dimensional MRI allowed for the visualization, segmentation, and volumetric measurement of the prostate from normal and genetically engineered animals, in vivo. Additionally, MRS performed on the prostate epithelia of probasin‐ErbB‐2Δ × Pten+/− mice identified changes in the relative concentrations of the metabolites choline and citrate, which was not observed in TRAMP mice. METHODS T1‐weighted MRI was performed on normal, TRAMP, probasin‐ErbB‐2/Her2/Neu (probasin‐ErbB‐2Δ), and probasin‐ErbB‐2Δ in the context of decreased Pten activity (probasin‐ErbB‐2Δ × Pten+/−) mice. Volume‐localized single‐voxel proton magnetic resonance spectroscopy (SVS 1H MRS) was also performed. CONCLUSIONS The data presented supports the use of combined MRI and MRS for the measurement of biochemical and morphometric alterations in mouse models of prostate cancer. Prostate © 2006 Wiley‐Liss, Inc.